We use cookies to make your experience better. To comply with the new e-Privacy directive, we need to ask for your consent to set the cookies. Learn more.
Visit us at booth #1A to explore how FUJIFILM Irvine Scientific, with newly acquired Shenandoah Biotechnology, now offers a portfolio of animal component-free (ACF) human recombinant growth factors. Manufactured in an ISO 9001:2015 certified facility under strict cGMP guidelines, providing manufacturers a single point of access to accelerate life science research and discovery, for cell and gene therapy development.
Presentation Details
Topic: Optimizing Cell Proliferation and Function for Immunotherapy with Recombinant Growth Factors & Cytokines
Speaker: Goncalo Regalo, PhD, Field Application Scientist, FUJIFILM Irvine Scientific
Date: September 20, 2022
Time: 3:15 PM EDT
Location: Tech Slam Area, Hynes Convention Center, Boston, MA
Attend our presentation to learn more about optimizing cell proliferation and function for immunotherapy with CTGrade Recombinant Human Proteins including:
- The role interleukins play in the regulation of adaptive cellular responses
- Developing recombinant growth factors and cytokines designed for cell-based therapies
- Achieving optimal results through scientifically driven selection of products to ensure predictable workflow performance in the proliferation and differentiation of T cells, natural killer (NK) cells, B cells, and chimeric antigen receptor (CAR-T) cells
- Importance of a raw material supplier with a strong Quality system
Poster Presentation
Title: Freeze, Thaw and Expand: Scale up T cell Workflow in Chemically Defined media.
Location: Poster Area | Hynes Convention Center, Boston, MA
A major challenge in the field of cell therapy is the difficulty in generating sufficient cell numbers with consistent clinical quality. Learn more about how maintaining a serum-free environment throughout the manufacturing workflow is critical for the reliable activation, genetic manipulation, expansion, cryopreservation, and recovery of T cells developed for therapeutic use.